Filing Details
- Accession Number:
- 0001209191-20-030494
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-05-19 16:33:13
- Reporting Period:
- 2020-05-15
- Accepted Time:
- 2020-05-19 16:33:13
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1789815 | Ourania Tatsis | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp, Chief Regulatory Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-05-15 | 10 | $276.35 | 12,848 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 17 | $279.93 | 12,831 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 21 | $281.23 | 12,810 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 10 | $284.30 | 12,800 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 20 | $286.12 | 12,780 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 33 | $287.61 | 12,747 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-05-15 | 9 | $288.38 | 12,738 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $279.93 (range $279.68 to $280.53).
- Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $281.23 (range $280.73 to $281.62).
- Open market sales reported on this line occurred at a weighted average price of $286.12 (range $285.79 to $286.44).
- Open market sales reported on this line occurred at a weighted average price of $287.61 (range $287.04 to $287.99).
- Open market sales reported on this line occurred at a weighted average price of $288.38 (range $288.20 to $288.47).
Billionaire Hedge Funds
